Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2023

11.05.2022 | Original Article

Role of Hepatitis C Infection in Acute Liver Injury/Acute Liver Failure in North America

verfasst von: Ashwin Rao, Jody A. Rule, Giuliana Cerro-Chiang, Richard T. Stravitz, Brendan M. McGuire, Goo Lee, Robert J. Fontana, William M. Lee

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

While hepatitis A and B are well-known causes of acute liver failure (ALF), few well-documented cases of hepatitis C virus (HCV) infection (absent preexisting liver disease or other liver insults) have been described that result in ALF. We reviewed the Acute Liver Failure Study Group registry for evidence of HCV as a primary or contributing cause to ALF.

Methods

From January 1998 to January 2017, 2,332 patients with ALF (INR ≥ 1.5, any degree of hepatic encephalopathy) and 667 with acute liver injury (ALI; INR ≥ 2.0, no hepatic encephalopathy) were enrolled. Anti-HCV testing was done routinely, with confirmatory RT-PCR testing for HCV RNA where necessary.

Results

A total of 136 patients were anti-HCV-antibody positive, as follows: 56 HCV RNA negative, 65 HCV RNA positive, and 8 with no result nor sera available for testing. Only three subjects with ALI/ALF were determined to represent acute HCV infection. Case 1: 47-year-old female with morbid obesity (BMI 52.4) developed ALF and recovered, experiencing anti-HCV seroconversion. Case 2: 37-year-old female using cocaine presented with ALI and fully recovered. Case 3: 54-year-old female developed ALF requiring transplantation and was anti-HCV negative but viremic prior to transplant experiencing anti-HCV seroconversion thereafter. Among 1636 APAP overdose patients, the 52 with concomitant chronic HCV had higher 3-week mortality than the 1584 without HCV (31% vs 17%, p = 0.01).

Conclusions

ALI/ALF solely related to acute hepatitis C infection is very rare. Chronic HCV infection, found in at least 65 (2.2%) of ALI/ALF patients studied, contributed to more severe outcomes in APAP ALI/ALF; ClinicalTrials.gov number, NCT000518440.
Trial Registration ClinicalTrials.gov number NCT000518440.
Literatur
1.
Zurück zum Zitat Polson J, Lee WM. American Association for the Study of Liver D. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179–1197.CrossRef Polson J, Lee WM. American Association for the Study of Liver D. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179–1197.CrossRef
2.
Zurück zum Zitat Bower WA, Johns M, Margolis HS et al. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007;102:2459–2463.CrossRef Bower WA, Johns M, Margolis HS et al. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007;102:2459–2463.CrossRef
3.
Zurück zum Zitat Germani G, Theocharidou E, Adam R et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol 2012;57:288–296.CrossRef Germani G, Theocharidou E, Adam R et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol 2012;57:288–296.CrossRef
4.
Zurück zum Zitat Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947–954.CrossRef Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947–954.CrossRef
5.
Zurück zum Zitat Acharya SK, Dasarathy S, Kumer TL et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996;23:1448–1455.CrossRef Acharya SK, Dasarathy S, Kumer TL et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996;23:1448–1455.CrossRef
6.
Zurück zum Zitat Acharya SK, Batra Y, Hazari S et al. Etiopathogenesis of acute hepatic failure: Eastern versus Western countries. J Gastroenterol Hepatol 2002;17:S268–S273.CrossRef Acharya SK, Batra Y, Hazari S et al. Etiopathogenesis of acute hepatic failure: Eastern versus Western countries. J Gastroenterol Hepatol 2002;17:S268–S273.CrossRef
7.
Zurück zum Zitat Bernal W, Auzinger G, Dhawan A et al. Acute liver failure. Lancet 2010;376:190–201.CrossRef Bernal W, Auzinger G, Dhawan A et al. Acute liver failure. Lancet 2010;376:190–201.CrossRef
8.
Zurück zum Zitat O’Grady JG, Alexander GJ, Hayllar KM et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439–445.CrossRef O’Grady JG, Alexander GJ, Hayllar KM et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439–445.CrossRef
9.
Zurück zum Zitat Farci P, Alter HJ, Shimoda A et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996;335:631–634.CrossRef Farci P, Alter HJ, Shimoda A et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996;335:631–634.CrossRef
10.
Zurück zum Zitat Kanzaki H, Takaki A, Yagi T et al. A case of fulminant liver failure associated with hepatitis C virus. Clin J Gastroenterol 2014;7:170–174.CrossRef Kanzaki H, Takaki A, Yagi T et al. A case of fulminant liver failure associated with hepatitis C virus. Clin J Gastroenterol 2014;7:170–174.CrossRef
11.
Zurück zum Zitat Thiel AM, Rissland J, Lammert F et al. Acute liver failure as a rare case of a frequent disease. Z Gastroenterol 2018;56:255–258. Thiel AM, Rissland J, Lammert F et al. Acute liver failure as a rare case of a frequent disease. Z Gastroenterol 2018;56:255–258.
12.
Zurück zum Zitat Tracy B, Shrestha R, Stein L, et al. Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure. Transpl Infect Dis 2017;19. Tracy B, Shrestha R, Stein L, et al. Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure. Transpl Infect Dis 2017;19.
13.
Zurück zum Zitat Younis BB, Arshad R, Khurhsid S et al. Fulminant hepatic failure (FHF) due to acute hepatitis C. Pak J Med Sci 2015;31:1009–1011. Younis BB, Arshad R, Khurhsid S et al. Fulminant hepatic failure (FHF) due to acute hepatitis C. Pak J Med Sci 2015;31:1009–1011.
14.
Zurück zum Zitat Yu ML, Hou NJ, Dai CY et al. Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin. Antimicrob Agents Chemother 2005;49:3986–3987.CrossRef Yu ML, Hou NJ, Dai CY et al. Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin. Antimicrob Agents Chemother 2005;49:3986–3987.CrossRef
15.
Zurück zum Zitat Koch DG, Speiser JL, Durkalski V et al. The natural history of severe acute liver injury. Am J Gastroenterol 2017;112:1389–1396.CrossRef Koch DG, Speiser JL, Durkalski V et al. The natural history of severe acute liver injury. Am J Gastroenterol 2017;112:1389–1396.CrossRef
16.
Zurück zum Zitat Brillanti S, Masci C, Miglioli M et al. Serum IgM antibodies to hepatitis C virus in acute and chronic hepatitis C. Arch Virol Suppl 1993;8:213–218. Brillanti S, Masci C, Miglioli M et al. Serum IgM antibodies to hepatitis C virus in acute and chronic hepatitis C. Arch Virol Suppl 1993;8:213–218.
17.
Zurück zum Zitat Ghany MG, Morgan TR. Panel A-IHCG. Hepatitis C guidance 2019 update: American Association for the study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 2020;71:686–721.CrossRef Ghany MG, Morgan TR. Panel A-IHCG. Hepatitis C guidance 2019 update: American Association for the study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 2020;71:686–721.CrossRef
18.
Zurück zum Zitat Centers for Disease C. Prevention Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013;62:362–365. Centers for Disease C. Prevention Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013;62:362–365.
19.
Zurück zum Zitat Cox AL, Netski DM, Mosbruger T et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005;40:951–958.CrossRef Cox AL, Netski DM, Mosbruger T et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005;40:951–958.CrossRef
20.
Zurück zum Zitat Glynn SA, Wright DJ, Kleinman SH et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005;45:994–1002.CrossRef Glynn SA, Wright DJ, Kleinman SH et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005;45:994–1002.CrossRef
21.
Zurück zum Zitat Khandelwal N, James LP, Sanders C, Larson AM, Lee WM. Acute Liver Failure Study Group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011;53:567–576.CrossRef Khandelwal N, James LP, Sanders C, Larson AM, Lee WM. Acute Liver Failure Study Group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011;53:567–576.CrossRef
22.
Zurück zum Zitat Fan R, Wang J, Du J. Association between body mass index and fatty liver risk: a dose-response analysis. Sci Rep 2018;8:15273.CrossRef Fan R, Wang J, Du J. Association between body mass index and fatty liver risk: a dose-response analysis. Sci Rep 2018;8:15273.CrossRef
23.
Zurück zum Zitat Loomis AK, Kabadi S, Preiss D et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. J Clin Endocrinol Metab 2016;101:945–952.CrossRef Loomis AK, Kabadi S, Preiss D et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. J Clin Endocrinol Metab 2016;101:945–952.CrossRef
24.
Zurück zum Zitat Saida T, Fukushima W, Ohfuji S et al. Effect modification of body mass index and body fat percentage on fatty liver disease in a Japanese population. J Gastroenterol Hepatol 2014;29:128–136.CrossRef Saida T, Fukushima W, Ohfuji S et al. Effect modification of body mass index and body fat percentage on fatty liver disease in a Japanese population. J Gastroenterol Hepatol 2014;29:128–136.CrossRef
25.
Zurück zum Zitat Morita S, Neto Dde S, Morita FH et al. Prevalence of non-alcoholic fatty liver disease and steatohepatitis risk factors in patients undergoing bariatric surgery. Obes Surg 2015;25:2335–2343.CrossRef Morita S, Neto Dde S, Morita FH et al. Prevalence of non-alcoholic fatty liver disease and steatohepatitis risk factors in patients undergoing bariatric surgery. Obes Surg 2015;25:2335–2343.CrossRef
26.
Zurück zum Zitat Kato T, Furusaka A, Miyamoto M et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 2001;64:334–339.CrossRef Kato T, Furusaka A, Miyamoto M et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 2001;64:334–339.CrossRef
27.
Zurück zum Zitat Kato T, Choi Y, Elmowalid G et al. Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology 2008;48:732–740.CrossRef Kato T, Choi Y, Elmowalid G et al. Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology 2008;48:732–740.CrossRef
28.
Zurück zum Zitat Loomba R, Rivera MM, McBurney R et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011;33:559–565.CrossRef Loomba R, Rivera MM, McBurney R et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011;33:559–565.CrossRef
29.
Zurück zum Zitat Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008;372:321–332.CrossRef Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008;372:321–332.CrossRef
30.
Zurück zum Zitat Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80–88.CrossRef Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80–88.CrossRef
31.
Zurück zum Zitat Horner SM. Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol 2014;426:1198–1209.CrossRef Horner SM. Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol 2014;426:1198–1209.CrossRef
32.
Zurück zum Zitat Kim H, Meyer K, Di Bisceglie AM et al. Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. J Virol 2013;87:5858–5867.CrossRef Kim H, Meyer K, Di Bisceglie AM et al. Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. J Virol 2013;87:5858–5867.CrossRef
33.
Zurück zum Zitat Mazumdar B, Kim H, Meyer K et al. Hepatitis C virus proteins inhibit C3 complement production. J Virol 2012;86:2221–2228.CrossRef Mazumdar B, Kim H, Meyer K et al. Hepatitis C virus proteins inhibit C3 complement production. J Virol 2012;86:2221–2228.CrossRef
34.
Zurück zum Zitat Banerjee A, Mazumdar B, Meyer K et al. Transcriptional repression of C4 complement by hepatitis C virus proteins. J Virol 2011;85:4157–4166.CrossRef Banerjee A, Mazumdar B, Meyer K et al. Transcriptional repression of C4 complement by hepatitis C virus proteins. J Virol 2011;85:4157–4166.CrossRef
35.
Zurück zum Zitat Kwon YC, Ray RB, Ray R. Hepatitis C virus infection: establishment of chronicity and liver disease progression. EXCLI J 2014;13:977–996. Kwon YC, Ray RB, Ray R. Hepatitis C virus infection: establishment of chronicity and liver disease progression. EXCLI J 2014;13:977–996.
39.
Zurück zum Zitat Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997;50:401–406.CrossRef Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997;50:401–406.CrossRef
40.
Zurück zum Zitat Larrea E, Beloqui O, Munoz-Navas MA, Civeira MP, Prieto J. Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Radic Biol Med 1998;24:1235–1241.CrossRef Larrea E, Beloqui O, Munoz-Navas MA, Civeira MP, Prieto J. Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Radic Biol Med 1998;24:1235–1241.CrossRef
41.
Zurück zum Zitat Barbaro G, Di LG, Ribersani M, Soldini M, Giancaspro G, Bellomo G et al. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 1999;30:774–782.CrossRef Barbaro G, Di LG, Ribersani M, Soldini M, Giancaspro G, Bellomo G et al. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 1999;30:774–782.CrossRef
42.
Zurück zum Zitat Busch MP, Murthy KK, Kleinman SH et al. Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood 2012;119:6326–6334.CrossRef Busch MP, Murthy KK, Kleinman SH et al. Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood 2012;119:6326–6334.CrossRef
Metadaten
Titel
Role of Hepatitis C Infection in Acute Liver Injury/Acute Liver Failure in North America
verfasst von
Ashwin Rao
Jody A. Rule
Giuliana Cerro-Chiang
Richard T. Stravitz
Brendan M. McGuire
Goo Lee
Robert J. Fontana
William M. Lee
Publikationsdatum
11.05.2022
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2023
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07524-6

Weitere Artikel der Ausgabe 1/2023

Digestive Diseases and Sciences 1/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.